Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG). Hertzberg M, et al. Among authors: kannourakis g. Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10. Haematologica. 2017. PMID: 28143954 Free PMC article. Clinical Trial.
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
White L, McCowage G, Kannourakis G, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri R, Lockwood L, Tiedemann K, et al. White L, et al. Among authors: kannourakis g. J Clin Oncol. 1994 Mar;12(3):522-31. doi: 10.1200/JCO.1994.12.3.522. J Clin Oncol. 1994. PMID: 8120550 Clinical Trial.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group. McCarthy N, et al. Among authors: kannourakis g. Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3. Breast. 2014. PMID: 24393617 Free article. Clinical Trial.
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A. Davis ID, et al. Among authors: kannourakis g. Ann Oncol. 2015 Jun;26(6):1118-1123. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701452 Free article. Clinical Trial.
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group. Zdenkowski N, et al. Among authors: kannourakis g. Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055. Epub 2016 Feb 9. Ann Oncol. 2016. PMID: 26861603 Free article. Clinical Trial.
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators. Martin AJ, et al. Among authors: kannourakis g. Gastric Cancer. 2018 May;21(3):473-480. doi: 10.1007/s10120-017-0754-1. Epub 2017 Aug 16. Gastric Cancer. 2018. PMID: 28815316 Clinical Trial.
Breast-cancer adjuvant therapy with zoledronic acid.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. Coleman RE, et al. N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25. N Engl J Med. 2011. PMID: 21995387 Free article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Pagani O, et al. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881463 Free PMC article. Clinical Trial.
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A, Stockler M, Martin A, Pavlakis N, Sjoquist K, Goldstein D, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Nott L, Snow S, Burge M, Harris D, Jonker D, Chua YJ, Epstein R, Bonaventura A, Kiely B. Vasista A, et al. Among authors: kannourakis g. Oncologist. 2019 Nov;24(11):e1102-e1107. doi: 10.1634/theoncologist.2018-0613. Epub 2019 Apr 1. Oncologist. 2019. PMID: 30936377 Free PMC article. Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Escudier B, et al. Among authors: kannourakis g. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823696 Free PMC article. Clinical Trial.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.
Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC; Severe Chronic Neutropenia International Registry. Rosenberg PS, et al. Among authors: kannourakis g. Blood. 2006 Jun 15;107(12):4628-35. doi: 10.1182/blood-2005-11-4370. Epub 2006 Feb 23. Blood. 2006. PMID: 16497969 Free PMC article.
A Role for MAIT Cells in Colorectal Cancer.
Berzins SP, Wallace ME, Kannourakis G, Kelly J. Berzins SP, et al. Among authors: kannourakis g. Front Immunol. 2020 May 20;11:949. doi: 10.3389/fimmu.2020.00949. eCollection 2020. Front Immunol. 2020. PMID: 32508830 Free PMC article. Review.
Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers.
Kelly J, Minoda Y, Meredith T, Cameron G, Philipp MS, Pellicci DG, Corbett AJ, Kurts C, Gray DH, Godfrey DI, Kannourakis G, Berzins SP. Kelly J, et al. Among authors: kannourakis g. Immunol Cell Biol. 2019 Sep;97(8):689-699. doi: 10.1111/imcb.12281. Epub 2019 Jul 19. Immunol Cell Biol. 2019. PMID: 31323167 Free PMC article.
Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.
West JA, Olsen SL, Mitchell JM, Priddle RE, Luke JM, Akefeldt SO, Henter JI, Turville C, Kannourakis G. West JA, et al. Among authors: kannourakis g. PLoS One. 2014 Oct 24;9(10):e109586. doi: 10.1371/journal.pone.0109586. eCollection 2014. PLoS One. 2014. PMID: 25343480 Free PMC article.
Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23.
Kvedaraite E, Lourda M, Han H, Tesi B, Mitchell J, Ideström M, Mouratidou N, Rassidakis G, von Bahr Greenwood T, Cohen-Aubart F, Jädersten M, Åkefeldt SO, Svensson M, Kannourakis G, Bryceson YT, Haroche J, Henter JI. Kvedaraite E, et al. Among authors: kannourakis g. Acta Paediatr. 2021 Apr;110(4):1315-1321. doi: 10.1111/apa.15590. Epub 2020 Oct 8. Acta Paediatr. 2021. PMID: 32975844 Free PMC article.
Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes.
Evrard M, Wynne-Jones E, Peng C, Kato Y, Christo SN, Fonseca R, Park SL, Burn TN, Osman M, Devi S, Chun J, Mueller SN, Kannourakis G, Berzins SP, Pellicci DG, Heath WR, Jameson SC, Mackay LK. Evrard M, et al. Among authors: kannourakis g. J Exp Med. 2022 Jan 3;219(1):e20210116. doi: 10.1084/jem.20210116. Epub 2021 Oct 22. J Exp Med. 2022. PMID: 34677611 Free PMC article.
Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia.
Rosenberg PS, Alter BP, Link DC, Stein S, Rodger E, Bolyard AA, Aprikyan AA, Bonilla MA, Dror Y, Kannourakis G, Newburger PE, Boxer LA, Dale DC. Rosenberg PS, et al. Among authors: kannourakis g. Br J Haematol. 2008 Jan;140(2):210-3. doi: 10.1111/j.1365-2141.2007.06897.x. Epub 2007 Nov 20. Br J Haematol. 2008. PMID: 18028488 Free PMC article.
The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.
Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, Kannourakis G, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C, Welte K. Dale DC, et al. Among authors: kannourakis g. Support Cancer Ther. 2006 Jul 1;3(4):220-31. doi: 10.3816/SCT.2006.n.020. Support Cancer Ther. 2006. PMID: 18632498
Glycogen storage disease.
Kannourakis G. Kannourakis G. Semin Hematol. 2002 Apr;39(2):103-6. doi: 10.1053/shem.2002.31920. Semin Hematol. 2002. PMID: 11957192 Review.
The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis.
Stuart SF, Bezawork-Geleta A, Areeb Z, Gomez J, Tsui V, Zulkifli A, Paradiso L, Jones J, Nguyen HPT, Putoczki TL, Licciardi PV, Kannourakis G, Morokoff AP, Achuthan AA, Luwor RB. Stuart SF, et al. Among authors: kannourakis g. Int J Mol Sci. 2023 Feb 8;24(4):3356. doi: 10.3390/ijms24043356. Int J Mol Sci. 2023. PMID: 36834778 Free PMC article.
SCL gene in human tumors.
Rockman S, Begley CG, Kannourakis G, Mann GJ, Dobrovic AN, Kefford RF, McGrath K. Rockman S, et al. Among authors: kannourakis g. Leukemia. 1992 Jul;6(7):623-5. Leukemia. 1992. PMID: 1625484
Divergent molecular networks program functionally distinct CD8+ skin-resident memory T cells.
Park SL, Christo SN, Wells AC, Gandolfo LC, Zaid A, Alexandre YO, Burn TN, Schröder J, Collins N, Han SJ, Guillaume SM, Evrard M, Castellucci C, Davies B, Osman M, Obers A, McDonald KM, Wang H, Mueller SN, Kannourakis G, Berzins SP, Mielke LA, Carbone FR, Kallies A, Speed TP, Belkaid Y, Mackay LK. Park SL, et al. Among authors: kannourakis g. Science. 2023 Dec;382(6674):1073-1079. doi: 10.1126/science.adi8885. Epub 2023 Nov 30. Science. 2023. PMID: 38033053
A three-stage developmental pathway for human Vγ9Vδ2 T cells within the postnatal thymus.
Perriman L, Tavakolinia N, Jalali S, Li S, Hickey PF, Amann-Zalcenstein D, Ho WWH, Baldwin TM, Piers AT, Konstantinov IE, Anderson J, Stanley EG, Licciardi PV, Kannourakis G, Naik SH, Koay HF, Mackay LK, Berzins SP, Pellicci DG. Perriman L, et al. Among authors: kannourakis g. Sci Immunol. 2023 Jul 21;8(85):eabo4365. doi: 10.1126/sciimmunol.abo4365. Epub 2023 Jul 14. Sci Immunol. 2023. PMID: 37450574
The Role of TIM-3 in Glioblastoma Progression.
Ahmady F, Sharma A, Achuthan AA, Kannourakis G, Luwor RB. Ahmady F, et al. Among authors: kannourakis g. Cells. 2025 Feb 27;14(5):346. doi: 10.3390/cells14050346. Cells. 2025. PMID: 40072074 Free PMC article. Review.
Advances in CRISPR/Cas systems-based cell and gene therapy.
Poddar A, Ahmady F, Prithviraj P, Luwor RB, Shukla R, Polash SA, Li H, Ramakrishna S, Kannourakis G, Jayachandran A. Poddar A, et al. Among authors: kannourakis g. Prog Mol Biol Transl Sci. 2024;208:161-183. doi: 10.1016/bs.pmbts.2024.07.005. Epub 2024 Aug 12. Prog Mol Biol Transl Sci. 2024. PMID: 39266181 Review.
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
Ciardiello F, Bang YJ, Cervantes A, Dvorkin M, Lopez CD, Metges JP, Sánchez Ruiz A, Calvo M, Strickland AH, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham RJ, Shen L. Ciardiello F, et al. Among authors: kannourakis g. Cancer Med. 2023 Jun;12(12):13145-13154. doi: 10.1002/cam4.5997. Epub 2023 Jun 1. Cancer Med. 2023. PMID: 37260158 Free PMC article. Clinical Trial.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
108 results